An emerging research tool to watch out for in oncology new product development
What's next beyond BTK inhibition in lymphomas and CLL?
Pulling disparate sources together to develop a more optimised approach to targeting oncoproteins
A look at some hot topics from the TARGETS/TRIPLE meeting in Boston
As we head into the long August Bank Holiday and Labor Day celebrations, I wanted to offer some…
How exploratory new biomarkers are paving the way
Finding rare thistles in the fields
How we can use AI to improve scientific writing and reports
Hot topics to follow at AACR22
Exploring new approaches to targeting cancer
What can we learn from various breast cancer trials?
Can a genomic signature help select patients more accurately for DDR therapies?
What are Gritstone up to behind the scenes and where are they headed in the near-term?
Can AI and deep learning help us re-program genetic defects with RNA therapies?
What can deep learning techniques tell us about NASH, Parkinson's, Alzheimer's or even cancer?
How can AI and ML speed up or improve our drug discovery efforts in oncology R&D?
New research is emerging which may have an impact on future trial designs as well as combination partners and even different tumour types.
Some intriguing convergence from two recent conferences offers new insights from an AI perspective
new approaches to applying translational research to the clinic in oncology R&D
